Inpharma 1251 - 19 Aug 2000

■ NX-211* shows greater antitumour activity thanthe topoisomerase I inhibitor lurtotecan in mice, sayresearchers from the US. They explain that NX-211 is aliposomal formulation of lurtotecan. In this study, miceimplanted with cells from 1 of 3 tumour cell linesreceived single or repeated IV doses of NX-211,lurtotecan or topotecan. Single-dose studies revealedsignificantly greater delays in tumour growth inNX-211, compared with lurtotecan and topotecan,recipients; the therapeutic index of NX-211 wasapproximately 3- to 14-fold greater than that oflurtotecan. Similarly, results of repeat-dose studiesrevealed a consistently greater antitumour efficacyamong NX-211, compared with lurtotecan andtopotecan, recipients. A greater number of NX-211,compared with lurtotecan and topotecan, recipientshad durable cures (as assessed at 60 days).* Gilead Sciences; phase I

Emerson DL, et al. Antitumor efficacy, pharmacokinetics, and biodistributionof NX 211: a low-clearance liposomal formulation of lurtotecan. Clinicalcancer research: an official journal of the American Association for CancerResearch 6: 2903-2912, Jul 2000 800837734

1

Inpharma 19 Aug 2000 No. 12511173-8324/10/1251-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved